COL18A1 and non-small cell lung carcinoma: This study took patients with advanced NSCLC as the research object, analyzed the prognostic factors of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy followed by INRT in the treatment of NSCLC, and explored its effectiveness.